Get started
Author

Youngeun Ha

ORCID: 0009-0004-3672-8148
Observed ORCID: 0009-0004-3672-8148
OpenAlex ID: A5061178928
Calnexin as a dual-role biomarker: antibody-based diagnosis and therapeutic targeting in lung cancer
2024 · Soyeon Lim, Youngeun Ha, et al. · BMB Reports · 8
PDF
Contactin-4 suppresses antitumor T cell responses by engaging amyloid precursor protein
2024 · Bu-Nam Jeon, Sujeong Kim, et al. · Science Immunology · 4
PDF
Abstract 2968: Development of anti-APP antibody targeting APP/CNTN4 axis as a novel cancer immunotherapy
2023 · Mi Young Cha, Youngeun Ha, et al. · Cancer Research · 1
PRL-3–sensitive cytoskeletal signaling mediates early airway epithelial responses to particulate matter
2026 · Hyungkyung Yoon, Moonhwan Choi, et al. · Respiratory Research
Abstract 4443: Preclinical development of GENA-104 ADC, an exatecan-based novel antibody-drug conjugate targeting CNTN4, for solid tumors
2026 · Mi Young Cha, Hyunkyung Yu, et al. · Cancer Research
Abstract 5635: Rational design of a bispecific ADC targeting ITGB4 and TROP2 for co-expressing solid tumors
2026 · Mi Young Cha, Jiyoung Lee, et al. · Cancer Research
Abstract 4442: Targeting ITGB4 with a topoisomerase I ADC: Preclinical antitumor activity in colorectal and head and neck cancers
2026 · Mi Young Cha, Hyunuk Kim, et al. · Cancer Research
Abstract 7290: Targeting APP with GENA-119B31: A novel approach to overcoming immune checkpoint inhibitor resistance in cancer immunotherapy
2025 · Mi Young Cha, Kitae Park, et al. · Cancer Research
Abstract 4790: Immunostimulatory effects of GENA-104A16, a monoclonal anti-CNTN4 antibody, on tumor-infiltrating lymphocytes in a colon cancer liver metastasis model
2025 · Hyunkyung Yu, Taebum Lee, et al. · Cancer Research
Abstract 4270: Targeting CNTN4 with exatecan-based antibody-drug conjugate for the treatment of solid tumors
2025 · Mi Young Cha, Mira Kim, et al. · Cancer Research
Abstract 740: CNTN4 as a novel target for solid cancer with antibody-drug conjugate
2024 · Mi Young Cha, Hyunuk Kim, et al. · Cancer Research
Abstract 1868: Novel immune checkpoint inhibitor: In vivo and in vitro efficacy of anti-CNTN4 antibody, GENA-104A16 in the models with increased CNTN4 expression
2023 · Mi Young Cha, Hyunkyung Yu, et al. · Cancer Research
Abstract 2862: Novel immune checkpoint protein CNTN4 and the preclinical efficacy of affinity matured anti-CNTN4 antibody GENA-104A16
2022 · Mi Young Cha, Hnkyung yu, et al. · Cancer Research
Abstract 1760: The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer
2022 · Hyunkyung Yu, Nathalie Bellocq, et al. · Cancer Research
Works count: 14
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type